CRMD CorMedix Inc.

3.16
-0.43  -12%
Previous Close 3.59
Open 3.42
Price To Book 3.47
Market Cap 82,560,874
Shares 26,126,859
Volume 197,371
Short Ratio 11.31
Av. Daily Volume 289,902
Stock charts supplied by TradingView

NewsSee all news

  1. CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    Company in process of submitting New Drug Application (NDA) for Neutrolin® for prevention of catheter-related blood stream infections via a rolling review granted by FDA Conference Call Scheduled for Today at 4:30 p.m.

  2. CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16

    BERKELEY HEIGHTS, N.J., March 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  3. CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

    BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  4. CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

    BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  5. CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA to be filed 1H 2020.
Neutrolin - LOCK-IT 100
Hemodialysis patients with central venous catheters
Phase 3 to be initiated pending funding.
Neutrolin - LOCK-IT 200
Oncology patients on Total Parental Nutrition (TPN)

Latest News

  1. CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    Company in process of submitting New Drug Application (NDA) for Neutrolin® for prevention of catheter-related blood stream infections via a rolling review granted by FDA Conference Call Scheduled for Today at 4:30 p.m.

  2. CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16

    BERKELEY HEIGHTS, N.J., March 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  3. CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

    BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  4. CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

    BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  5. CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  6. CorMedix Inc. to Report Third Quarter 2019 Financial Results and Provide a Corporate Update on November 14

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  7. CorMedix Inc. Announces a Change to its Senior Leadership

    BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  8. CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  9. CorMedix Inc. Announces Exercises of Outstanding Warrants

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of

  10. CorMedix Inc. to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of